Edward van der Horst
Chief Tech/Sci/R&D Officer bij SENSEI BIOTHERAPEUTICS, INC.
Vermogen: 58 874 $ op 31-03-2024
Profiel
Edward van der Horst is currently the Chief Scientific Officer at Sensei Biotherapeutics, Inc. He previously worked as the Senior Director-Preclinical Development at Igenica Biotherapeutics, Inc. from 2010 to 2017 and as the VP-Discovery Biology & Preclinical Drug at Zenith Epigenetics Ltd.
from 2017 to 2019.
Dr. van der Horst obtained a graduate degree from Ludwig-Maximilians-Universität München and a doctorate degree from Max Planck Institute of Biochemistry.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-02-2024 | 56 070 ( 0.22% ) | 58 874 $ | 31-03-2024 |
Actieve functies van Edward van der Horst
| Bedrijven | Functie | Begin |
|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 07-12-2022 |
Eerdere bekende functies van Edward van der Horst
| Bedrijven | Functie | Einde |
|---|---|---|
Zenith Epigenetics Ltd.
 Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Corporate Officer/Principal | 01-08-2019 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01-01-2017 |
Opleiding van Edward van der Horst
| Ludwig-Maximilians-Universität München | Graduate Degree |
| Max Planck Institute of Biochemistry | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Commercial Services |
